Novo Nordisk’s weight problems drug Wegovy cleared to deal with stay illness MASH
Novo Nordisk’s weight problems drug Wegovy was cleared by U.S. regulators on Friday to deal with an more and more frequent liver illness, including to the checklist of circumstances for which the blockbuster remedy is now authorized.
The Meals and Drug Administration granted accelerated approval to Wegovy for sufferers with metabolic dysfunction-associated steatohepatitis, or MASH, with average to superior liver scarring. The choice was primarily based on Section 3 outcomes exhibiting that the drug helped enhance liver scarring, or fibrosis, and resolve signs.
Many individuals with weight problems develop fatty liver illness, which may then progress to a extreme type that’s MASH. MASH causes fibrosis, which may then advance to much more severe scarring known as cirrhosis, which then results in liver most cancers or the necessity for a liver transplant.
This text is unique to STAT+ subscribers
Unlock this text — plus every day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
